- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02887196
Attitudes Toward Physical Activity and Nutrition Intervention During Cancer Treatment (CARE)
Study Overview
Status
Conditions
Detailed Description
In this cross sectional, longitudinal, observational study, 25 women will be followed through their treatment for stage I-III breast cancer. The women will be asked to provide their opinions and desires for lifestyle intervention at four timepoints throughout treatment. In addition to qualitative data, basic clinical data will be collected (anthropometrics, vital signs, dietary intake, and physical activity). The primary goal of this pilot study is to investigate the anthropometric and behavioral changes that occur in patients undergoing adjuvant chemotherapy for breast cancer.
Aim 1: To better understand patients' attitudes toward and perceived barriers to nutrition and physical activity interventions during neoplastic treatment.
Hypothesis: Patients' reported attitudes, motivation, and perceived barriers will change throughout treatment.
Aim 2: To measure the physical and metabolic changes that occur throughout neoplastic treatment for breast cancer.
Hypothesis: Over 50% of the participants will gain body weight during treatment and metabolic parameters will trend with body weight change.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808-4124
- Pennington Biomedical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female
- ≥18 years of age
- Diagnosed with stage I, II or III breast cancer with plans to undergo endocrine and/or chemotherapy treatment (radiation in combination with one or more of these therapies is acceptable)
- Willing to complete up to 4 clinic visits
Exclusion Criteria:
- Have received neoadjuvant therapy for current diagnosis
- Currently receiving adjuvant chemotherapy or other adjuvant therapy that was initiated prior to study enrollment
- History of cancer and neoplastic treatment
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perceived attitudes towards lifestyle interventions
Time Frame: 9 months
|
Qualitative data collected via semi-structured interview
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diet
Time Frame: 9 months
|
24 hour recall (ASA24) to assess food intake changes throughout treatment
|
9 months
|
|
Physical Activity
Time Frame: 9 months
|
Wrist worn Actigraph accelerometer to assess activity changes throughout treatment
|
9 months
|
|
Body Weight
Time Frame: 9 months
|
Body weight change throughout treatment
|
9 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anne Gilmore, PhD, Pennington Biomedical Research Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PBRC 2016-050
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Dana-Farber Cancer InstituteIncyte CorporationActive, not recruitingInflammatory Breast Cancer (IBC)United States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCCompletedBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Xijing HospitalActive, not recruitingBreast Cancer | Breast Cancer (Triple Negative Breast Cancer (TNBC))China
-
BerGenBio ASAMerck Sharp & Dohme LLCTerminatedTriple Negative Breast Cancer | Inflammatory Breast Cancer Stage IVSpain, United States, United Kingdom, Norway
-
CytomX TherapeuticsCompletedNeoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 NegativeUnited States, Spain, Korea, Republic of
-
Emory UniversityCompletedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of Breast | Cancer of the Breast | Human Mammary CarcinomaUnited States
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Beaumont HospitalRecruitingRobotic Surgery | Breast Reconstruction | DIEP Flap Breast Reconstruction | Breast Cancer, Breast NeoplasmsIreland